A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (CF) Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (CF) Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
The purpose of this study evaluates the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who were heterozygous for F508del and a minimal function mutation (F/MF participants).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
San Francisco, California 94143, United States
St. Petersburg, Florida 33701, United States
Boston, Massachusetts 02114, United States
Columbia, Missouri 65212, United States
St Louis, Missouri 63110, United States
Toledo, Ohio 43606, United States
Memphis, Tennessee 38105, United States
Erlangen, Germany
Jena, Germany
Petach Tikvah, Israel
Christchurch Hospital, New Zealand
Bristol, United Kingdom